Peer review reports
From: Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Original Submission | ||
---|---|---|
27 Jan 2023 | Submitted | Original manuscript |
13 Mar 2023 | Reviewed | Reviewer Report |
16 Mar 2023 | Reviewed | Reviewer Report |
27 Mar 2023 | Reviewed | Reviewer Report |
6 Apr 2023 | Author responded | Author comments - Wei Hua |
Resubmission - Version 2 | ||
6 Apr 2023 | Submitted | Manuscript version 2 |
12 Apr 2023 | Reviewed | Reviewer Report |
21 Apr 2023 | Reviewed | Reviewer Report |
22 Apr 2023 | Reviewed | Reviewer Report |
15 May 2023 | Author responded | Author comments - Wei Hua |
Resubmission - Version 3 | ||
15 May 2023 | Submitted | Manuscript version 3 |
16 May 2023 | Author responded | Author comments - Wei Hua |
Resubmission - Version 4 | ||
16 May 2023 | Submitted | Manuscript version 4 |
5 Jun 2023 | Reviewed | Reviewer Report |
Resubmission - Version 5 | ||
Submitted | Manuscript version 5 | |
Publishing | ||
6 Jun 2023 | Editorially accepted | |
14 Jun 2023 | Article published | 10.1186/s12885-023-11043-6 |